动脉粥样硬化性心血管疾病风险评估对中国高血压防治的启示

高血压是心脑血管疾病最为重要的危险因素之一。对高血压患者进行动脉粥样硬化性心血管疾病（ASCVD）风险评估是临床工作中不可忽视的重要环节。目前我国常用的风险评估模型主要有美国心脏病学会（ACC）/美国心脏协会（AHA）制定的动脉粥样硬化性心血管疾病风险评估模型（PCE模型）、Framingham心血管疾病风险评估模型（FRS模型）以及中国缺血性心血管疾病（ICVD）风险评估模型（China-PAR模型）。三者在纳入人群、终点事件、计算方法等方面既有相似又有不同,各自之间既有优势又有不足。文章对三种模型的特点以及临床应用进行了综述。

The Implications of Atherosclerotic Cardiovascular Disease Disk Assessment for the Prevention and Treatment of Hypertention in Chana

Hypertension is one of the most important risk factors for cardiovascular and cerebrovascular diseases. The risk assessment of atherosclerotic cardiovascular disease (ASCVD) in patients with hypertension is an important part of clinical work. At present, the risk assessment models commonly used in China mainly include the atherosclerotic cardiovascular disease risk assessment model (PCE model) developed by the American College of Cardiology (ACC)/American Heart Association (AHA), and the Framingham cardiovascular disease risk assessment model (FRS Model) and China''s ischemic cardiovascular disease (ICVD) risk assessment model (China-PAR model). The three are similar and different in terms of inclusion, end-point events, and calculation methods, and each has its own advantages and disadvantages. The article reviews the characteristics and clinical applications of the three models.